OC50 2025: Arthur Kuan
Arthur Kuan at Nasdaq on CG Oncology’s IPO day ARTHUR KUAN CEO / CHAIRMAN CG ONCOLOGY WHY: The 34-year-old leads research for bladder cancer treatments that investors have called “game changers.” Went public in January 2024 after raising $380M in an initial public offering, marking the largest IPO for an Read More










